Cardiology Letters 2023, 32(4):271-280
The role of calcium/calmodulin-dependent protein kinase 2 in serious cardiovascular pathologies and its clinical potential
- 1 Katedry farmakológie a toxikológie, Farmaceutická fakulta, Univerzita Komenského v Bratislave
- 2 Ústav pre výskum srdca, Centrum experimentálnej medicíny, Slovenská Akadémia Vied, Bratislava, Slovenská republika
Cardiac pathologies such as arrhythmias, myocardial infarction or chronic heart failure are among the significant epidemiological, therapeutic and financial challenges of our time but, despite this, new pharmacotherapeutic tools for their management are still insufficient. Calcium plays a critical role in the pathophysiology of heart, as it mediates the excitationcontraction and excitation-transcriptional coupling in myocytes. Its dysregulation leads to the occurrence of many serious phenotypes of cell damage, from contractile dysfunction to cell death or pathological remodeling, and subsequently dysfunction of the heart as an organ. Despite, or precisely because of this ubiquitous nature of calcium, there are only few practically used groups of drugs in the therapy, such as L-type calcium channel antagonists or calcium sensitizers. Calcium/calmodulin-dependent protein kinase 2 (CaMKII) plays a pivotal role in the regulation of calcium turnover, regulating its influx into the cytoplasm, its removal into the sarcoendoplasmic reticulum, as well as calcium-dependent transcription and metabolism. This is precisely why its pharmacological modulation or inhibition is an interesting research goal, especially in the context of the lack of new treatment procedures in the above-mentioned serious cardiac pathologies, and may represent an important new step in their treatment. The aim of this review article is to provide an insight into its action in the heart, the possibilities of its regulation at the level of post-translational modifications and experimental or clinical possibilities in the future therapy of serious cardiac pathologies.
Keywords: calcium; CaMKII; ischemia, reperfusion; arrhythmias; heart failure
Published: April 1, 2023 Show citation
References
- Pellicena P, Schulman H. CaMKII inhibitors: from research tools to therapeutic agents. Front Pharmacol. 2014;5:21.
Go to original source... - Zhang M, Zhang J, Zhang W, Hu Q, Jin L, Xie P, et al. CaMKII-delta9 Induces Cardiomyocyte Death to Promote Cardiomyopathy and Heart Failure. Front Cardiovasc Med. 2021;8:820416.
Go to original source... - Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM, Anderson ME. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol. 2012;52(5):1135-44.
Go to original source... - Erickson JR. Mechanisms of CaMKII Activation in the Heart. Front Pharmacol. 2014;5:59.
Go to original source... - Fazal L, Laudette M, Paula-Gomes S, Pons S, Conte C, Tortosa F, et al. Multifunctional Mitochondrial Epac1 Controls Myocardial Cell Death. Circ Res. 2017;120(4):645-57.
Go to original source... - Zhang T, Zhang Y, Cui M, Jin L, Wang Y, Lv F, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016;22(2):175-82.
Go to original source... - Tao W, Lee J, Chen X, Diaz-Alonso J, Zhou J, Pleasure S, et al. Synaptic memory requires CaMKII. Elife. 2021;10.
Go to original source... - Hansen DV, Tung JJ, Jackson PK. CaMKII and polo-like kinase 1 sequentially phosphorylate the cytostatic factor Emi2/XErp1 to trigger its destruction and meiotic exit. Proc Natl Acad Sci U S A. 2006;103(3):608-13.
Go to original source... - Li Y, Sirenko S, Riordon DR, Yang D, Spurgeon H, Lakatta EG, et al. CaMKII-dependent phosphorylation regulates basal cardiac pacemaker function via modulation of local Ca2+ releases. Am J Physiol Heart Circ Physiol. 2016;311(3):H532-44.
Go to original source... - Borbiev T, Verin AD, Birukova A, Liu F, Crow MT, Garcia JG. Role of CaM kinase II and ERK activation in thrombin-induced endothelial cell barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L43-54.
Go to original source... - Mattiazzi A, Bassani RA, Escobar AL, Palomeque J, Valverde CA, Vila Petroff M, et al. Chasing cardiac physiology and pathology down the CaMKII cascade. Am J Physiol Heart Circ Physiol. 2015;308(10):H1177-91.
Go to original source... - Reyes Gaido OE, Nkashama LJ, Schole KL, Wang Q, Umapathi P, Mesubi OO, et al. CaMKII as a Therapeutic Target in Cardiovascular Disease. Annu Rev Pharmacol Toxicol. 2023;63:249-72.
Go to original source... - Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502(7471):372-6.
Go to original source... - Sarkar P, Davis KA, Puhl HL, 3rd, Veetil JV, Nguyen TA, Vogel SS. Deciphering CaMKII Multimerization Using Fluorescence Correlation Spectroscopy and Homo-FRET Analysis. Biophys J. 2017;112(6):1270-81.
Go to original source... - Sloutsky R, Stratton MM. Functional implications of CaMKII alternative splicing. Eur J Neurosci. 2021;54(8):6780-94.
Go to original source... - Bell JR, Raaijmakers AJ, Curl CL, Reichelt ME, Harding TW, Bei A, et al. Cardiac CaMKIIdelta splice variants exhibit target signaling specificity and confer sex-selective arrhythmogenic actions in the ischemic-reperfused heart. Int J Cardiol. 2015;181:288-96.
Go to original source... - Kreusser MM, Lehmann LH, Keranov S, Hoting MO, Oehl U, Kohlhaas M, et al. Cardiac CaM Kinase II genes delta and gamma contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation. 2014;130(15):1262-73.
Go to original source... - Hudmon A, Schulman H. Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J. 2002;364(Pt 3):593-611.
Go to original source... - Meyer T, Hanson PI, Stryer L, Schulman H. Calmodulin trapping by calcium-calmodulin-dependent protein kinase. Science. 1992;256(5060):1199-202.
Go to original source... - Colbran RJ. Inactivation of Ca2+/calmodulin-dependent protein kinase II by basal autophosphorylation. J Biol Chem. 1993;268(10):7163-70.
Go to original source... - Jama AM, Fenton J, Robertson SD, Torok K. Time-dependent autoinactivation of phospho-Thr286-alphaCa2+/ calmodulin-dependent protein kinase II. J Biol Chem. 2009;284(41):28146-55.
Go to original source... - Munevar S, Gangopadhyay SS, Gallant C, Colombo B, Sellke FW, Morgan KG. CaMKIIT287 and T305 regulate historydependent increases in alpha agonist-induced vascular tone. J Cell Mol Med. 2008;12(1):219-26.
Go to original source... - Yilmaz M, Gangopadhyay SS, Leavis P, Grabarek Z, Morgan KG. Phosphorylation at Ser(2)(6) in the ATP-binding site of Ca(2) (+)/calmodulin-dependent kinase II as a mechanism for switching off the kinase activity. Biosci Rep. 2013;33(2).
Go to original source... - Kim I, Je HD, Gallant C, Zhan Q, Riper DV, Badwey JA, et al. Ca2+-calmodulin-dependent protein kinase II-dependent activation of contractility in ferret aorta. J Physiol. 2000;526 Pt 2(Pt 2):367-74.
Go to original source... - Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51(4):468-73.
Go to original source... - Kirchhefer U, Schmitz W, Scholz H, Neumann J. Activity of cAMPdependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res. 1999;42(1):254-61.
Go to original source... - Fischer TH, Eiringhaus J, Dybkova N, Forster A, Herting J, Kleinwachter A, et al. Ca(2+) /calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca(2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail. 2014;16(12):1292-300.
Go to original source... - Rajtik T, Goncalvesova E, Varga ZV, Leszek P, Kusmierczyk M, Hulman M, et al. Posttranslational modifications of calcium/ calmodulin-dependent protein kinase IIdelta and its downstream signaling in human failing hearts. Am J Transl Res. 2017;9(8):3573-85.
- Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133(3):462-74.
Go to original source... - Anderson ME. Pathways for CaMKII activation in disease. Heart Rhythm. 2011;8(9):1501-3.
Go to original source... - Palomeque J, Rueda OV, Sapia L, Valverde CA, Salas M, Petroff MV, et al. Angiotensin II-induced oxidative stress resets the Ca2+ dependence of Ca2+-calmodulin protein kinase II and promotes a death pathway conserved across different species. Circ Res. 2009;105(12):1204-12.
Go to original source... - Konstantinidis K, Bezzerides VJ, Lai L, Isbell HM, Wei AC, Wu Y, et al. MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. J Clin Invest. 2020;130(9):4663-78.
Go to original source... - Song YH, Cho H, Ryu SY, Yoon JY, Park SH, Noh CI, et al. L-type Ca(2+) channel facilitation mediated by H(2)O(2)-induced activation of CaMKII in rat ventricular myocytes. J Mol Cell Cardiol. 2010;48(4):773-80.
Go to original source... - Espejo MS, Aiello I, Sepulveda M, Vila Petroff MG, Aiello EA, De Giusti VC. The reduced myofilament responsiveness to calcium contributes to the negative force-frequency relationship in rat cardiomyocytes: role of reactive oxygen species and p-38 map kinase. Pflugers Arch. 2017;469(12):1663-73.
Go to original source... - Lu S, Liao Z, Lu X, Katschinski DM, Mercola M, Chen J, et al. Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O-linked GlcNAcylation and CaMKII Activation in Mouse Ventricular Myocytes. Circ Res. 2020;126(10):e80-e96.
Go to original source... - Federico M, Portiansky EL, Sommese L, Alvarado FJ, Blanco PG, Zanuzzi CN, et al. Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance. J Physiol. 2017;595(12):4089-108.
Go to original source... - Hegyi B, Fasoli A, Ko CY, Van BW, Alim CC, Shen EY, et al. CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia. Circ Res. 2021;129(1):98-113.
Go to original source... - Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014;289(28):19458-65.
Go to original source... - Gutierrez DA, Fernandez-Tenorio M, Ogrodnik J, Niggli E. NO-dependent CaMKII activation during beta-adrenergic stimulation of cardiac muscle. Cardiovasc Res. 2013;100(3):392-401.
Go to original source... - Erickson JR, Nichols CB, Uchinoumi H, Stein ML, Bossuyt J, Bers DM. S-Nitrosylation Induces Both Autonomous Activation and Inhibition of Calcium/Calmodulin-dependent Protein Kinase II delta. J Biol Chem. 2015;290(42):25646-56.
Go to original source... - Meng Y, Ding P, Wang H, Yang X, Wang Z, Nie D, et al. Ca(2+)/ calmodulin-dependent protein kinase II inhibition reduces myocardial fatty acid uptake and oxidation after myocardial infarction. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(6):159120.
Go to original source... - Wang J, Cheng X, Zhao H, Yang Q, Xu Z. Downregulation of the zinc transporter SLC39A13 (ZIP13) is responsible for the activation of CaMKII at reperfusion and leads to myocardial ischemia/reperfusion injury in mouse hearts. J Mol Cell Cardiol. 2021;152:69-79.
Go to original source... - Yao Y, Li F, Zhang M, Jin L, Xie P, Liu D, et al. Targeting CaMKII-delta9 Ameliorates Cardiac Ischemia/Reperfusion Injury by Inhibiting Myocardial Inflammation. Circ Res. 2022;130(6):887-903.
Go to original source... - Neuhof C, Neuhof H. Calpain system and its involvement in myocardial ischemia and reperfusion injury. World J Cardiol. 2014;6(7):638-52.
Go to original source... - Toldo S, Mauro AG, Cutter Z, Abbate A. Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2018;315(6):H1553-H68.
Go to original source... - Bugger H, Pfeil K. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165768.
Go to original source... - Pittas K, Vrachatis DA, Angelidis C, Tsoucala S, Giannopoulos G, Deftereos S. The Role of Calcium Handling Mechanisms in Reperfusion Injury. Curr Pharm Des. 2018;24(34):4077-89.
Go to original source... - Hegyi B, Polonen RP, Hellgren KT, Ko CY, Ginsburg KS, Bossuyt J, et al. Cardiomyocyte Na(+) and Ca(2+) mishandling drives vicious cycle involving CaMKII, ROS, and ryanodine receptors. Basic Res Cardiol. 2021;116(1):58.
Go to original source... - Adameova A, Carnicka S, Rajtik T, Szobi A, Nemcekova M, Svec P, et al. Upregulation of CaMKIIdelta during ischaemia-reperfusion is associated with reperfusion-induced arrhythmias and mechanical dysfunction of the rat heart: involvement of sarcolemmal Ca2+-cycling proteins. Can J Physiol Pharmacol. 2012;90(8):1127-34.
Go to original source... - Szobi A, Rajtik T, Carnicka S, Ravingerova T, Adameova A. Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: effects on programmed necrotic and apoptotic cell death. Mol Cell Biochem. 2014;388(1-2):269-76.
Go to original source... - Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, et al. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca(2+)/ Calmodulin-Dependent Protein Kinase II delta Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. Circulation. 2018;138(22):2530-44.
Go to original source... - Hund TJ, Decker KF, Kanter E, Mohler PJ, Boyden PA, Schuessler RB, et al. Role of activated CaMKII in abnormal calcium homeostasis and I(Na) remodeling after myocardial infarction: insights from mathematical modeling. J Mol Cell Cardiol. 2008;45(3):420-8.
Go to original source... - Kompa AR, Khong FL, Zhang Y, Nguyen C, Edgley AJ, Woodman OL, et al. NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction. Life Sci. 2022;289:120220.
Go to original source... - Tao B, Liu Z, Wei F, Fan S, Cui S, Xia H, et al. Over-expression of Kv4.3 gene reverses cardiac remodeling and transient-outward K(+) current (Ito) reduction via CaMKII inhibition in myocardial infarction. Biomed Pharmacother. 2020;132:110896.
Go to original source... - Gray CB, Suetomi T, Xiang S, Mishra S, Blackwood EA, Glembotski CC, et al. CaMKIIdelta subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF-kappaB and TNF-alpha. J Mol Cell Cardiol. 2017;103:48-55.
Go to original source... - Grueter CE, Colbran RJ, Anderson ME. CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. J Mol Med (Berl). 2007;85(1):5-14.
Go to original source... - Hund TJ, Mohler PJ. Role of CaMKII in cardiac arrhythmias. Trends Cardiovasc Med. 2015;25(5):392-7.
Go to original source... - Bezzerides VJ, Caballero A, Wang S, Ai Y, Hylind RJ, Lu F, et al. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca(2+)/Calmodulin-Dependent Kinase II. Circulation. 2019;140(5):405-19.
Go to original source... - Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm. 2015;12(2):440-8.
Go to original source... - Thiel WH, Chen B, Hund TJ, Koval OM, Purohit A, Song LS, et al. Proarrhythmic defects in Timothy syndrome require calmodulin kinase II. Circulation. 2008;118(22):2225-34.
Go to original source... - Ho HT, Liu B, Snyder JS, Lou Q, Brundage EA, Velez-Cortes F, et al. Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides. Cardiovasc Res. 2014;101(1):165-74.
Go to original source... - Hu Q, Chen H, Shen C, Zhang B, Weng X, Sun X, et al. Impact and potential mechanism of effects of chronic moderate alcohol consumption on cardiac function in aldehyde dehydrogenase 2 gene heterozygous mice. Alcohol Clin Exp Res. 2022;46(5):707-23.
Go to original source... - Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation. 2006;114(13):1352-9.
Go to original source... - Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, Gigena MS, et al. The cardiac-specific nuclear delta(B) isoform of Ca2+/ calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002;277(2):1261-7.
Go to original source... - Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116(7):1853-64.
Go to original source... - Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J, Jr., Bers DM, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92(8):912-9.
Go to original source... - Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, et al. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181(3):968-75.
Go to original source... - Wong MH, Samal AB, Lee M, Vlach J, Novikov N, Niedziela-Majka A, et al. The KN-93 Molecule Inhibits Calcium/CalmodulinDependent Protein Kinase II (CaMKII) Activity by Binding to Ca(2+)/CaM. J Mol Biol. 2019;431(7):1440-59.
Go to original source... - Ledoux J, Chartier D, Leblanc N. Inhibitors of calmodulindependent protein kinase are nonspecific blockers of voltage-dependent K+ channels in vascular myocytes. J Pharmacol Exp Ther. 1999;290(3):1165-74.
Go to original source... - Rezazadeh S, Claydon TW, Fedida D. KN-93 (2-[N-(2hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)] amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther. 2006;317(1):292-9.
Go to original source... - Kong LH, Gu XM, Wu F, Jin ZX, Zhou JJ. CaMKII inhibition mitigates ischemia/reperfusion-elicited calpain activation and the damage to membrane skeleton proteins in isolated rat hearts. Biochem Biophys Res Commun. 2017;491(3):687-92.
Go to original source... - Liu Y, Shao Q, Cheng HJ, Li T, Zhang X, Callahan MF, et al. Chronic Ca(2+)/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure. J Pharmacol Exp Ther. 2021;377(3):316-25.
Go to original source... - Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky E, et al. CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc Res. 2007;73(4):689-98.
Go to original source... - Li GZ, Hu YH, Lu YN, Yang QY, Fu D, Chen F, et al. CaMKII and Ca(V)3.2 T-type calcium channel mediate Connexin43-dependent inflammation by activating astrocytes in vincristine-induced neuropathic pain. Cell Biol Toxicol. 2021.
- Ni Y, Deng J, Bai H, Liu C, Liu X, Wang X. CaMKII inhibitor KN-93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p-VEGFR2 and STAT3 pathways. J Cell Mol Med. 2022;26(2):312-25.
Go to original source... - Lebek S, Plossl A, Baier M, Mustroph J, Tarnowski D, Lucht CM, et al. The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity. J Mol Cell Cardiol. 2018;118:159-68.
Go to original source... - Mustroph J, Drzymalski M, Baier M, Pabel S, Biedermann A, Memmel B, et al. The oral Ca/calmodulin-dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure. ESC Heart Fail. 2020;7(5):287183.
Go to original source... - Boyle AJ, Schultz C, Selvanayagam JB, Moir S, Kovacs R, Dib N, et al. Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2021;6(7):762-8.
Go to original source... - Nassal D, Gratz D, Hund TJ. Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart. Front Pharmacol. 2020;11:35.
Go to original source... - Yeh T-yT, Yeap XY, Mullick AE. Abstract 438: Downregulation of Ca<sup>2+</sup>/calmodulin-dependent Protein Kinase Type II Delta in the Heart by Antisense Oligonucleotides Mitigates Development of Post-infarct Ventricular Arrhythmias. Circulation Research. 2020;127(Suppl_1):A438-A.
Go to original source...

